A - Human Necessities – 61 – K
Patent
A - Human Necessities
61
K
A61K 48/00 (2006.01) A61K 31/19 (2006.01) A61K 31/70 (2006.01) A61K 31/7088 (2006.01) A61K 38/18 (2006.01) A61K 39/385 (2006.01) A61K 39/395 (2006.01) A61P 3/10 (2006.01) C07K 14/52 (2006.01) C07K 14/71 (2006.01) C07K 16/28 (2006.01) C07K 19/00 (2006.01)
Patent
CA 2519787
Methods of treating diabetes in mammals, particularly humans, by blocking or inhibiting VEGF-mediated activity. A preferred inhibitor of VEGF-mediated activity is a VEGF antagonist such as a VEGF trap capable of binding and blocking VEGF.
L'invention concerne des méthodes permettant de traiter le diabète chez des mammifères, notamment chez l'homme, par blocage ou inhibition de l'activité induite par le facteur de croissance endothéliale. Un inhibiteur préféré de l'activité induite par le facteur de croissance endothéliale est un antagoniste du facteur de croissance endothéliale, tel qu'un piège du facteur de croissance endothéliale apte à fixer et à bloquer le facteur de croissance endothéliale.
Sleeman Mark W.
Wiegand Stanley J.
Blake Cassels & Graydon Llp
Regeneron Pharmaceuticals Inc.
LandOfFree
Methods of treating diabetes by blocking vegf-mediated activity does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of treating diabetes by blocking vegf-mediated activity, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of treating diabetes by blocking vegf-mediated activity will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-2048129